Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Bringing cancer therapies to market is complex. Especially for aggressive and therapy-resistant cancers, like ovarian cancer.
The inability of the platinum and taxane treatments to sustain a positive response after initial success presents a serious setback in ovarian cancer treatment. Learn how the innovative clinical program explores Niraparib, and whether it can help prevent the progression of ovarian cancer in platinum-sensitive patients.
Download the article now to find out the importance of this study in taking us one step closer to saving the lives of those who are diagnosed with ovarian cancer.
downloadExplore Our Key Related Services
Please fill out this form to access your resource.